Genomics-Guided Off-Label Treatment: Prospective Evaluation
The “Wild West” era of off-label cancer treatment—where clinicians prescribe non-approved drugs based on scientific intuition and hope—is facing a necessary reckoning. For years, patients with exhausted treatment options have navigated a precarious landscape of high-cost, high-toxicity therapies with little to no systematic oversight. However, the long-term results of the Drug Rediscovery Protocol (DRUP) provide … Read more
